This review highlights the challenges and emerging methods, such as the prothrombinase-induced clotting test, for accurately measuring the anticoagulant activity of oral Factor Xa inhibitors in the clinical laboratory.
Answers are grounded in this paper and cite their sources.
Accurate monitoring of oral Factor Xa inhibitors requires calibrated PT or anti-Xa assays; leaves open PiCT validation in prospective studies.
Oral anticoagulation therapy is currently undergoing great changes with the development and use of several new medications. The newer drugs have a more specific mechanism of action for inhibiting coagulation and do not require continuous monitoring like their predecessor. Their efficacy and safety has been proven, but problems arise in the clinical laboratory with developing accurate procedures to measure the therapy when needed. Methods being used are the prothrombin time and anti-factor Xa chromogenic assay which require calibration with the drug being measured. The prothrombinase-induced clotting test shows promise as a measure for Xa inhibitors. The article reviews the oral Factor Xa inhibitor9s clinical usefulness, effects on current laboratory coagulation tests and methods for measuring their anticoagulant activity. ABBREVIATIONS:CYP – cytochrome; DOAC – direct oral anticoagulant; DVT – deep venous thrombosis; INR – international normalized ratio; PE – pulmonary embolism; PiCT – prothrombinase-induced clotting time; PT – prothrombin time; APTT – activated partial thromboplastin time.
No takes yet. Share an insight, caveat, or question.
Melissa White (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: